A

References

Abee, C. 2011a. (Michale E. Keeling Center for Comparative Medicine and Research of the University of Texas MD Anderson Cancer Center, Bastrop, TX). Letter to Jeffrey Kahn: Chimpanzee mAb studies with attachments: Importance of chimpanzees in mAb research.pdf, Responses to IOM committee questions on mAb research with chimpanzees.pdf. September 30, 2011.

Abee, C. 2011b. (Michale E. Keeling Center for Comparative Medicine and Research of the University of Texas MD Anderson Cancer Center, Bastrop, TX). Email to authors: Chimpanzee studies and provision of research resources with attachments: Keeling Center from the University of Texas, KCCMR: Chimpanzee studies by year and type.pdf. July 1, 2011.

Abee, C. 2011c. (Michale E. Keeling Center for Comparative Medicine and Research of the University of Texas MD Anderson Cancer Center, Bastrop, TX). Email to authors: IOM chimp study—verification of numbers and ages of chimpanzees at the Michale E. Keeling Center for Comparative Medicine and Research. May 17, 2011.

Abee, C., M. Lammey, T. Rowell, J. VandeBerg, and S. Zola. 2011. Conference call with the directors of the Yerkes, New Iberia, Alamogordo, Southwest, and MD Anderson chimpanzee centers, Washington, DC, July 1, 2011.

Alnylam Pharmaceuticals. 2011. Phase 2b study of aln-rsv01 in lung transplant patients infected with respiratory syncytial virus (RSV). ClinicalTrials.gov: A service of the U.S. National Institutes of Health. http://clinicaltrials.gov/ct2/show/NCT01065935?term=nct01065935&rank=1NLMIdentifier:NCT01065935 (accessed August 24, 2011).

Altaweel, L., Z. Chen, M. Moayeri, X. Cui, Y. Li, J. Su, Y. Fitz, S. Johnson, S. H. Leppla, R. Purcell, and P. Q. Eichacker. 2011. Delayed treatment with w1-mab, a chimpanzee-derived monoclonal antibody against protective antigen, reduces mortality from challenges with anthrax edema or lethal toxin in rats and with anthrax spores in mice. Crit Care Med 39(6):1439-1447.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement



Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 71
A References Abee, C. 2011a. (Michale E. Keeling Center for Comparative Medicine and Research of the University of Texas MD Anderson Cancer Center, Bastrop, TX). Letter to Jeffrey Kahn: Chimpanzee mAb studies with attachments: Importance of chimpanzees in mAb research.pdf, Responses to IOM committee questions on mAb research with chimpanzees.pdf. September 30, 2011. Abee, C. 2011b. (Michale E. Keeling Center for Comparative Medicine and Research of the University of Texas MD Anderson Cancer Center, Bastrop, TX). Email to authors: Chimpanzee studies and provision of research resources with attachments: Keeling Center from the University of Texas, KCCMR: Chimpanzee studies by year and type.pdf. July 1, 2011. Abee, C. 2011c. (Michale E. Keeling Center for Comparative Medicine and Research of the University of Texas MD Anderson Cancer Center, Bastrop, TX). Email to authors: IOM chimp study—verification of numbers and ages of chimpanzees at the Michale E. Keeling Center for Comparative Medicine and Research. May 17, 2011. Abee, C., M. Lammey, T. Rowell, J. VandeBerg, and S. Zola. 2011. Conference call with the directors of the Yerkes, New Iberia, Alamogordo, Southwest, and MD Anderson chimpanzee centers, Washington, DC, July 1, 2011. Alnylam Pharmaceuticals. 2011. Phase 2b study of aln-rsv01 in lung transplant patients infected with respiratory syncytial virus (RSV). ClinicalTrials.gov: A service of the U.S. National Institutes of Health. http://clinicaltrials.gov/ct2/ show/NCT01065935?term=nct01065935&rank=1NLMIdentifier:NCT01065935 (accessed August 24, 2011). Altaweel, L., Z. Chen, M. Moayeri, X. Cui, Y. Li, J. Su, Y. Fitz, S. Johnson, S. H. Leppla, R. Purcell, and P. Q. Eichacker. 2011. Delayed treatment with w1-mab, a chimpanzee-derived monoclonal antibody against protective antigen, reduces mortality from challenges with anthrax edema or lethal toxin in rats and with anthrax spores in mice. Crit Care Med 39(6):1439-1447. 71

OCR for page 71
72 ASSESSING THE NECESSITY OF THE CHIMPANZEE An, Z. 2010. Monoclonal antibodies—a proven and rapidly expanding therapeutic modality for human diseases. Protein Cell 1(4):319-330. Animal Welfare Act (New Zealand). 1999. Public Act 1999, no. 142. Date of Assent 14 October 1999. Australian Government National Health and Medical Research Council. 2003. Policy on the use of non-human primates for scientific purposes. http://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/ea14.pdf (accessed October 213, 2011). AZA (Association of Zoos and Aquariums) Ape TAG. 2010. Chimpanzee (Pan troglodytes) care manual. Silver Spring, MD: Association of Zoos and Aquariums. Bailey, J. 2008. An assessment of the role of chimpanzees in AIDS vaccine research. ALTA 36(4):381-428. Bailey, J. 2010a. An assessment of the use of chimpanzees in hepatitis C research past, present and future: Validity of the chimpanzee model. ALTA 38(5):387-418. Bailey, J. 2010b. An assessment of the use of chimpanzees in hepatitis C research past, present and future: 2. Alternative replacement methods. ALTA 38(6):471-494. Bassett, S. E., K. M. Brasky, and R. E. Lanford. 1998. Analysis of hepatitis C virus-inoculated chimpanzees reveals unexpected clinical profiles. J Virol 72(4):2589-2599. Bassett, S. E., D. L. Thomas, K. M. Brasky, and R. E. Lanford. 1999. Viral persistence, antibody to e1 and e2, and hypervariable region 1 sequence stability in hepatitis C virus-inoculated chimpanzees. J Virol 73(2):1118- 1126. Bateson, P. 2011. Review of research using non-human primates: Report of a panel chaired by Professor Sir Patrick Bateson FRS. Medical Research Council (MRC). London, England. Beck, A., T. Wurch, C. Bailly, and N. Corvaia. 2010. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 10(5):345-352. Becker, P. D., N. Legrand, C. M. van Geelen, M. Noerder, N. D. Huntington, A. Lim, E. Yasuda, S. A. Diehl, F. A. Scheeren, M. Ott, K. Weijer, H. Wedemeyer, J. P. Di Santo, T. Beaumont, C. A. Guzman, and H. Spits. 2010. Generation of human antigen-specific monoclonal IgM antibodies using vaccinated “human immune system” mice. PLoS One 5(10). Bem, R. A., J. B. Domachowske, and H. F. Rosenberg. 2011. Animal models of human respiratory syncytial virus disease. Am J Physiol Lung Cell Mol Physiol 301(2):L148-L156. Ben-Yehudah, A., C. A. T. Easley, B. P. Hermann, C. Castro, C. Simerly, K. E. Orwig, S. Mitalipov, and G. Schatten. 2010. Systems biology discoveries using non-human primate pluripotent stem and germ cells: Novel gene and

OCR for page 71
73 APPENDIX A genomic imprinting interactions as well as unique expression patterns. Stem Cell Res Ther 1(3):24. Bennett, B. T., C. R. Abee, and R. Henrickson. 1995. Nonhuman primates in biomedical research. 2 vols., American College of Laboratory Animal Medicine Series. San Diego, CA: Academic Press. Bettauer, R. H. 2010. Chimpanzees in hepatitis C virus research: 1998-2007. J Med Primatol 39(1):9-23. Bettauer, R. H. 2011. Systematic review of chimpanzee use in monoclonal antibody research and drug development: 1981-2010. ALTEX 28(2):103- 116. Bissig, K. D., S. F. Wieland, P. Tran, M. Isogawa, T. T. Le, F. V. Chisari, and I. M. Verma. 2010. Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. J Clin Invest 120(3):924- 930. Blanco, J. C., M. S. Boukhvalova, K. A. Shirey, G. A. Prince, and S. N. Vogel. 2010. New insights for development of a safe and protective RSV vaccine. Hum Vaccin 6(6):482-492. Boonstra, A., L. J. van der Laan, T. Vanwolleghem, and H. L. Janssen. 2009. Experimental models for hepatitis C viral infection. Hepatology 50(5):1646- 1655. BPRC (Biomedical Primate Research Centre). 2011. Animal welfare: Relocation of chimpanzees. http://www.bprc.nl/BPRCE/L3/RelocChimps.html (accessed September 30, 2011). Bukh, J., X. Forns, S. U. Emerson, and R. H. Purcell. 2001. Studies of hepatitis C virus in chimpanzees and their importance for vaccine development. Intervirology 44(2-3):132-142. Byrd, L. G., and G. A. Prince. 1997. Animal models of respiratory syncytial virus infection. CID 25:1363-1368. Carroll, S. S., S. Ludmerer, L. Handt, K. Koeplinger, N. Y. R. Zhang, D. Graham, M. E. Davies, M. MacCoss, D. Hazuda, and D. B. Olsen. 2009. Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzees. Antimicrob Agents Chemother 53(3):926-934. Catanese, M. T., H. Ansuini, R. Graziani, T. Huby, M. Moreau, J. K. Ball, G. Paonessa, C. M. Rice, R. Cortese, A. Vitelli, and A. Nicosia. 2010. Role of scavenger receptor class B type in hepatitis C virus entry: Kinetics and molecular determinants. J Virol 84(1):34-43. CBER (Center for Biologics Evaluation and Research) and CDER (Center for Drug Evaluation and Research). 2009. Guidance for industry. Rockville, MD: U.S. Department of Health and Human Services, Food and Drug Administration. Chapman, K., N. Pullen, M. Graham, and I. Ragan. 2007. Preclinical safety testing of monoclonal antibodies: The significance of species relevance. Nat Rev Drug Discov 6(2):120-126.

OCR for page 71
74 ASSESSING THE NECESSITY OF THE CHIMPANZEE Chapman, K., N. Pullen, L. Coney, M. Dempster, L. Andrews, J. Bajramovic, P. Baldrick, L. Buckley, A. Jacobs, G. Hale, C. Green, I. Ragan, and V. Robinson. 2009. Preclinical development of monoclonal antibodies: Considerations for the use of non-human primates. MAbs 1(5):505-516. Chen, Z., P. Earl, J. Americo, I. Damon, S. K. Smith, Y. H. Zhou, F. Yu, A. Sebrell, S. Emerson, G. Cohen, R. J. Eisenberg, J. Svitel, P. Schuck, W. Satterfield, B. Moss, and R. Purcell. 2006a. Chimpanzee/human mAbs to vaccinia virus b5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus. Proc Natl Acad Sci USA 103(6):1882- 1887. Chen, Z., M. Moayeri, Y. H. Zhou, S. Leppla, S. Emerson, A. Sebrell, F. Yu, J. Svitel, P. Schuck, M. St. Claire, and R. Purcell. 2006b. Efficient neutralization of anthrax toxin by chimpanzee monoclonal antibodies against protective antigen. J Infect Dis 193(5):625-633. Chen, C. M., Y. He, L. Lu, H. B. Lim, R. L. Tripathi, T. Middleton, L. E. Hernandez, D. W. Beno, M. A. Long, W. M. Kati, T. D. Bosse, D. P. Larson, R. Wagner, R. E. Lanford, W. E. Kohlbrenner, D. J. Kempf, T. J. Pilot-Matias, and A. Molla. 2007a. Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model. Antimicrob Agents Chemother 51(12):4290-4296. Chen, Z., P. Earl, J. Americo, I. Damon, S. K. Smith, F. Yu, A. Sebrell, S. Emerson, G. Cohen, R. J. Eisenberg, I. Gorshkova, P. Schuck, W. Satterfield, B. Moss, and R. Purcell. 2007b. Characterization of chimpanzee/human monoclonal antibodies to vaccinia virus a33 glycoprotein and its variola virus homolog in vitro and in a vaccinia virus mouse protection model. J Virol 81(17):8989-8995. Chen, Z., M. Moayeri, D. Crown, S. Emerson, I. Gorshkova, P. Schuck, S. H. Leppla, and R. H. Purcell. 2009. Novel chimpanzee/human monoclonal antibodies that neutralize anthrax lethal factor, and evidence for possible synergy with anti-protective antigen antibody. Infect Immun 77(9):3902-3908. Chen, A. A., D. K. Thomas, L. L. Ong, R. E. Schwartz, T. R. Golub, and S. N. Bhatia. 2011a. Humanized mice with ectopic artificial liver tissues. Proc Natl Acad Sci USA 108(29):11842-11847. Chen, Z., K. Chumakov, E. Dragunsky, D. Kouiavskaia, M. Makiya, A. Neverov, G. Rezapkin, A. Sebrell, and R. Purcell. 2011b. Chimpanzee-human monoclonal antibodies for treatment of chronic poliovirus excretors and emergency postexposure prophylaxis. J Virol 85(9):4354-4362. Chen, Z., R. Schneerson, J. Lovchik, C. R. Lyons, H. Zhao, Z. Dai, J. Kubler-Kielb, S. H. Leppla, and R. H. Purcell. 2011c. Pre- and postexposure protection against virulent anthrax infection in mice by humanized monoclonal antibodies to bacillus anthracis capsule. Proc Natl Acad Sci USA 108(2):739-744. Chin, J., R. L. Magoffin, L. A. Shearer, J. H. Schieble, and E. H. Lennette. 1969. Field evaluation of a respiratory syncytial virus vaccine and a trivalent

OCR for page 71
75 APPENDIX A parainfluenza virus vaccine in a pediatric population. Am J Epidemiol 89(4):449-463. Choo, Q. L., G. Kuo, A. J. Weiner, L. R. Overby, D. W. Bradley, and M. Houghton. 1989. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244(4902):359-362. Choo, Q. L., G. Kuo, R. Ralston, A. Weiner, D. Chien, G. Van Nest, J. Han, K. Berger, K. Thudium, C. Kuo et al. 1994. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci USA 91(4):1294- 1298. Cohen, J. 2007a. The endangered lab chimp. Science 315(5811):450-452. Cohen, J. 2007b. NIH to end chimp breeding for research. Science 316(5829):1265. CHMP (Committee for Medicinal Products for Human Use). 2011. CHMP: Overview. http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/ general/general_content_000095.jsp&murl=menus/about_us/about_us.jsp& mid=WC0b01ac0580028c7a (accessed September 16, 2011). Congress of Spain, IX Legislature. 2008. Official bulletin of the general courts (No. 19). http://www.congreso.es/public_oficiales/L9/CONG/BOCG/D/D_ 019.PDF (accessed August 23, 2011). Cooper, S., A. L. Erickson, E. J. Adams, J. Kansopon, A. J. Weiner, D. Y. Chien, M. Houghton, P. Parham, and C. M. Walker. 1999. Analysis of a successful immune response against hepatitis C virus. Immunity 10(4):439-449. Corballis, M. C. 2002. From hand to mouth: The origins of language. Princeton, NJ: Princeton University Press. Council of Europe. 2006. Appendix A of the European convention for the protection of vertebrate animals used for experimental and other scientific purposes (ETS No. 123) guidelinges for accomodation and care of animals (article 5 of the convention) approved by the multilateral consulation. Council of Europe. Strasbourg. Couto, L. B., and A. A. Kolykhalov. 2006. Animal models for HCV study. In Hepatitis C viruses: Genomes and molecular biology, edited by S.-L. Tan. Wymondham, Norfolk, UK: Horizon Bioscience. Dahari, H., S. M. Feinstone, and M. E. Major. 2010. Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins. Gastroenterology 139(3):965-974. de Jong, Y. P., C. M. Rice, and A. Ploss. 2010. New horizons for studying human hepatotropic infections. J Clin Invest 120(3):650-653. de Marco, A. 2011. Biotechnological applications of recombinant single-domain antibody fragments. Microb Cell Fact 10:44. De Vos, R., C. Verslype, E. Depla, J. Fevery, B. Van Damme, V. Desmet, and T. Roskams. 2002. Ultrastructural visualization of hepatitis C virus components in human and primate liver biopsies. J Hepatol 37(3):370-379. Demarest, S. J., and S. M. Glaser. 2008. Antibody therapeutics, antibody engineering, and the merits of protein stability. Curr Opin Drug Discov Devel 11(5):675-687.

OCR for page 71
76 ASSESSING THE NECESSITY OF THE CHIMPANZEE DeVincenzo, J., R. Lambkin-Williams, T. Wilkinson, J. Cehelsky, S. Nochur, E. Walsh, R. Meyers, J. Gollob, and A. Vaishnaw. 2010. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci USA 107(19):8800- 8805. DHS (U.S. Department of Homeland Security). 2007. Care and use of animals in research.. Washington, DC: U.S. Government, Management Directives System. Domachowske, J. B., C. A. Bonville, and H. F. Rosenberg. 2004. Animal models for studying respiratory syncytial virus infection and its long term effects on lung function. Pediatr Infect Dis J 23(Suppl):S228-S234. Dorner, M., J. A. Horwitz, J. B. Robbins, W. T. Barry, Q. Feng, K. Mu, C. T. Jones, J. W. Schoggins, M. T. Catanese, D. R. Burton, M. Law, C. M. Rice, and A. Ploss. 2011. A genetically humanized mouse model for hepatitis C virus infection. Nature 474(7350):208-211. Eastwood, D., L. Findlay, S. Poole, C. Bird, M. Wadhwa, M. Moore, C. Burns, R. Thorpe, and R. Stebbings. 2010. Monoclonal antibody tgn1412 trial failure explained by species differences in cd28 expression on cd4+ effector memory T-cells. Br J Pharmacol 161(3):512-526. Ehrlich, P. H., Z. A. Moustafa, K. E. Harfeldt, C. Isaacson, and L. Ostberg. 1990. Potential of primate monoclonal antibodies to substitute for human antibodies: Nucleotide sequence of chimpanzee fab fragments. Hum Antibodies Hybridomas 1(1):23-26. Else, J. G. 2011. (Yerkes National Primate Research Center, Atlanta, GA). Email to authors: Chimpanzee ages with file attachment: yerkeschimpagereport.pdf. October 31, 2011. EMEA (European Medicines Agency). 2008. ICH topic m3 (r2) non-clinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. European Medincines Agency. London, England. EMEA. 2011a. ICH guideline S6 (R1)—preclinical safety evaluation of biotechnology-derived pharmaceuticals. EMA/CHMP/ICH/731268/1998 European Medicines Agency. EMEA. 2011b. CHMP assessment report, victrelis. http://www.ema.europa.eu/ docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/ 002332/WC500109789.pdf (accessed September 13, 2011). Enard, W., M. Przeworski, S. E. Fisher, C. S. Lai, V. Wiebe, T. Kitano, A. P. Monaco, and S. Paabo. 2002. Molecular evolution of FOXP2, a gene involved in speech and language. Nature 418(6900):869-872. Erickson, A. L., Y. Kimura, S. Igarashi, J. Eichelberger, M. Houghton, J. Sidney, D. McKinney, A. Sette, A. L. Hughes, and C. M. Walker. 2001. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 15(6):883-895.

OCR for page 71
77 APPENDIX A European Communities, and Office for Official Publications. 1986. Council directive on the approximation of laws, regulations and administrative provisions of member states regarding the protection of animals used for experimental and other scientific purposes. Official Journal of the European Communities No. L 358(18. 12. 86):28 p. European Parliament. 2007. Declaration of the European Parliament on primates in scientific experiments. European Parliament. European Union. 2010. Directive 2010/63/EU of the European parliament and of the council of 22 September 2010 on the protection of animals used for scientific purposes. Official Journal of the European Union No. L 276/33 (20. 10. 2010). FDA (U.S. Food and Drug Administration). 1986. OKT3: Ortho pharmaceutical corporation: Summary basis of approval of muromonab-cd3. http://www.foiservices.com/ (accessed (September 8, 2011). FDA. 2011a. Title 21—food and drugs—chapter 1—subchapter D—drugs for human use part 314 application for FDA approval to market a new drug (21CFR314). http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?cfrpart= cfrsearch.cfm?cfrpart=314&showfr=1&subpartnode=21:5.0.1.1.4.9 (accessed September 20, 2011). FDA. 2011b. Title 21—food and drugs—chapter 1—subchapter F—biologics part 601 licensing (21CFR601). http://www.accessdata.fda.gov/scripts/cdrh/ cfdocs/cfcfr/CFRSearch.cfm?CFRPart=601&showFR=1&subpartNode=21: 7.0.1.1.2.8 (accessed September 20, 2011). Folgori, A., S. Capone, L. Ruggeri, A. Meola, E. Sporeno, B. B. Ercole, M. Pezzanera, R. Tafi, M. Arcuri, E. Fattori, A. Lahm, A. Luzzago, A. Vitelli, S. Colloca, R. Cortese, and A. Nicosia. 2006. A T-cell HCV vaccine eliciting effective immunity against heterologous Fulginiti, V. A., J. J. Eller, O. F. Sieber, J. W. Joyner, M. Minamitani, and G. Meiklejohn. 1969. Respiratory virus immunization. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol 89(4):435-448. Galun, E., T. Burakova, M. Ketzinel, I. Lubin, E. Shezen, Y. Kahana, A. Eid, Y. Ilan, A. Rivkind, G. Pizov et al. 1995. Hepatitis C virus viremia in SCID-->BNX mouse chimera. J Infect Dis 172(1):25-30. Garrone, P., A. C. Fluckiger, P. E. Mangeot, E. Gauthier, P. Dupeyrot-Lacas, J. Mancip, A. Cangialosi, I. Du Chene, R. LeGrand, I. Mangeot, D. Lavillette, B. Bellier, F. L. Cosset, F. Tangy, D. Klatzmann, and C. Dalba. 2011. A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci Transl Med 3(94):94ra71. Gewin, V. 2011. Hepatitis C mouse model a major milestone: Development paves the way for testing potential vaccines. Nature News. http://www.nature.com/ news/2011/110608/full/news.2011.356.html (accessed October 13, 2011).

OCR for page 71
78 ASSESSING THE NECESSITY OF THE CHIMPANZEE Gibbs, R. A., J. Rogers, M. G. Katze, R. Bumgarner, G. M. Weinstock, E. R. Mardis, K. A. Remington, R. L. Strausberg, J. C. Venter, R. K. Wilson, M. A. Batzer, C. D. Bustamante, E. E. Eichler, M. W. Hahn, R. C. Hardison, K. D. Makova, W. Miller, A. Milosavljevic, R. E. Palermo, A. Siepel, J. M. Sikela, T. Attaway, S. Bell, K. E. Bernard, C. J. Buhay, M. N. Chandrabose, M. Dao, C. Davis, K. D. Delehaunty, Y. Ding, H. H. Dinh, S. Dugan-Rocha, L. A. Fulton, R. A. Gabisi, T. T. Garner, J. Godfrey, A. C. Hawes, J. Hernandez, A S. Hines, M. Holder, J. Hume, S. N. Jhangiani, V. Joshi, Z. M. Khan, E. F. Kirkness, A. Cree, R. G. Fowler, S. Lee, L. R. Lewis, Z. Li, Y. S. Liu, S. M. Moore, D. Muzny, L. V. Nazareth, D. N. Ngo, G. O. Okwuonu, G. Pai, D. Parker, H. A. Paul, C. Pfannkoch, C. S. Pohl, Y. H. Rogers, S. J. Ruiz, Sabo, J. Santibanez, B. W. Schneider, S. M. Smith, E. Sodergren, A. F. Svatek, T. R. Utterback, S. Vattathil, W. Warren, C. S. White, A. T. Chinwalla, Y. Feng, A. L. Halpern, L. W. Hillier, X. Huang, P. Minx, J. O. Nelson, K. H. Pepin, X. Qin, G. G. Sutton, E. Venter, B. P. Walenz, J. W. Wallis, K. C. Worley, S. P. Yang, S. M. Jones, M. A. Marra, M. Rocchi, J. E. Schein, R. Baertsch, L. Clarke, M. Csuros, J. Glasscock, R. A. Harris, P. Havlak, A. R. Jackson, H. Jiang, Y. Liu, D. N. Messina, Y. Shen, H. X. Song, T. Wylie, L. Zhang, E. Birney, K. Han, M. K. Konkel, J. Lee, A. F. Smit, B. Ullmer, H. Wang, J. Xing, R. Burhans, Z. Cheng, J. E. Karro, J. Ma, B. Raney, X. She, M. J. Cox, J. P. Demuth, L. J. Dumas, S. G. Han, J. Hopkins, A. Karimpour-Fard, Y. H. Kim, J. R. Pollack, T. Vinar, C. Addo-Quaye, J. Degenhardt, A. Denby, M. J. Hubisz, A. Indap, C. Kosiol, B. T. Lahn, H. A. Lawson, A. Marklein, R. Nielsen, E. J. Vallender, A. G. Clark, B. Ferguson, R. D. Hernandez, K. Hirani, H. Kehrer-Sawatzki, J. Kolb, S. Patil, L. L. Pu, Y. Ren, D. G. Smith, D. A. Wheeler, I. Schenck, E. V. Ball, R. Chen, D. N. Cooper, B. Giardine, F. Hsu, W. J. Kent, A. Lesk, D. L. Nelson, E. O’Brien W. K. Prufer, P. D. Stenson, J. C. Wallace, H. Ke, X. M. Liu, P. Wang, A. P. Xiang, F. Yang, G. P. Barber, D. Haussler, D. Karolchik, A. D. Kern, R. M. Kuhn, K. E. Smith, and A. S. Zwieg. 2007. Evolutionary and biomedical insights from the rhesus macaque genome. Science 316(5822):222-234. GlaxoSmithKline. 2011. Use of non-human primates (NHPs) in the discovery and development of medicines and vaccines. http://www.gsk.com/policies/GSK- public-position-on-NHP.pdf (accessed July 27, 2011). Goncalvez, A. P., R. Men, C. Wernly, R. H. Purcell, and C. J. Lai. 2004a. Chimpanzee fab fragments and a derived humanized immunoglobulin g1 antibody that efficiently cross-neutralize dengue type 1 and type 2 viruses. J Virol 78(23):12910-12918. Goncalvez, A. P., R. H. Purcell, and C. J. Lai. 2004b. Epitope determinants of a chimpanzee fab antibody that efficiently cross-neutralizes dengue type 1 and type 2 viruses map to inside and in close proximity to fusion loop of the dengue type 2 virus envelope glycoprotein. J Virol 78(23):12919-12928.

OCR for page 71
79 APPENDIX A Goncalvez, A. P., R. E. Engle, M. St. Claire, R. H. Purcell, and C. J. Lai. 2007. Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci USA 104(22):9422-9427. Goncalvez, A. P., C. H. Chien, K. Tubthong, I. Gorshkova, C. Roll, O. Donau, P. Schuck, S. Yoksan, S. D. Wang, R. H. Purcell, and C. J. Lai. 2008. Humanized monoclonal antibodies derived from chimpanzee fabs protect against Japanese encephalitis virus in vitro and in vivo. J Virol 82(14):7009- 7021. Graham, B. S. 2011. Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol Rev 239(1):149- 166. Halliday, J., P. Klenerman, and E. Barnes. 2011. Vaccination for hepatitis C virus: Closing in on an evasive target. Expert Rev Vaccines 10(5):659-672. Harcourt, J. L., H. Caidi, L. J. Anderson, and L. M. Haynes. 2011. Evaluation of the calu-3 cell line as a model of in vitro respiratory syncytial virus infection. J Virol Methods 174(1-2):144-149. Hartung, T. 2010. Comparative analysis of the revised directive 2010/63/EU for the protection of laboratory animals with its predecessor 86/609/EEC—a T4 report. ALTEX 27(4):285-303. HHS (U.S. Department of Health and Human Services). 2005. Code of Federal Regulations title 45 public welfare. Washington, DC: U.S. National Institutes of Health, Office of Human Subjects Research. HHS. 2011a. Costs for maintaining humane care and welfare of chimpanzees. http://grants.nih.gov/grants/policy/air/cost_for_caring_housing_of_chimpan zees_20110609.htm (accessed July 20, 2011). HHS. 2011b. NIH statement on the Alamogordo Primate Facility chimpanzees. http://grants.nih.gov/grants/policy/air/nih_alamogordo_statement_20110104. htm (accessed September 9, 2011). HHS. 2011c. Operation and maintenance of a chimpanzee facility: NHLBI-csb- (rr)-ss-2011-264-kjm. https://www.fbo.gov/spg/HHS/NIH/OAM/NHLBI-CSB- (RR)-SS-2011-264-KJM/listing.html (accessed August 24, 2011). HHS. 2011d. Response to the Physicians Committee for Responsible Medicine petition for administrative action April 8, 2011. http://grants.nih.gov/grants/ policy/air/physicians_committee_response_20110408.htm (accessed October 20, 2011). Horner, V., J. D. Carter, M. Suchak, and F. B. de Waal. 2011. Spontaneous prosocial choice by chimpanzees. Proc Natl Acad Sci USA 108(33):13847- 13851. Hosea, N. A. 2011. Drug design tools—in silico, in vitro and in vivo ADME/PK prediction and interpretation: Is PK in monkey an essential part of a good human PK prediction? Curr Top Med Chem 11(4):351-357. Houghton, M. 2011. Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses. Immunol Rev 239(1):99-108.

OCR for page 71
80 ASSESSING THE NECESSITY OF THE CHIMPANZEE Houghton, M., and S. Abrignani. 2005. Prospects for a vaccine against the hepatitis C virus. Nature 436(7053):961-966. The Humane Society of the United States. 2010. The HSUS urges Department of Health and Human Services to retire 202 chimpanzees. Press release, August 18. Gaithersburg, MD: The Humane Society of the United States. ICH Harmonized Tripartite Guideline. 2011. Preclinical safety evaluation of biotechnology derived pharmaceuticals S6(R1). http://www.ich.org/fileadmin/ Public_Web_Site/ICH_Products/Guidelines/Safety/S6_R1/Step4/S6_R1_Guide line.pdf (accessed October 13, 2011). Ilyas, J. A., and J. M. Vierling. 2011. An overview of emerging therapies for the treatment of chronic hepatitis C. Clin Liver Dis 15(3):515-536. Ings, R. M. 2009. Microdosing: A valuable tool for accelerating drug development and the role of bioanalytical methods in meeting the challenge. Bioanalysis 1(7):1293-1305. Iwarson, S., E. Tabor, H. C. Thomas, A. Goodall, J. Waters, P. Snoy, J. W. Shih, and R. J. Gerety. 1985. Neutralization of hepatitis B virus infectivity by a murine monoclonal antibody: An experimental study in the chimpanzee. J Med Virol 16(1):89-96. Jacobson, I. M., J. G. McHutchison, G. Dusheiko, A. M. Di Bisceglie, K. R. Reddy, N. H. Bzowej, P. Marcellin, A. J. Muir, P. Ferenci, R. Flisiak, J. George, M. Rizzetto, D. Shouval, R. Sola, R. A. Terg, E. M. Yoshida, N. Adda, L. Bengtsson, A. J. Sankoh, T. L. Kieffer, S. George, R. S. Kauffman, and S. Zeuzem. 2011. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364(25):2405-2416. Jensen, D. M. 2011. A new era of hepatitis C therapy begins. N Engl J Med 364(13):1272-1274. Kapoor, A., P. Simmonds, G. Gerold, N. Qaisar, K. Jain, J. A. Henriquez, C. Firth, D. L. Hirschberg, C. M. Rice, S. Shields, and W. I. Lipkin. 2011. Characterization of a canine homolog of hepatitis C virus. Proc Natl Acad Sci USA 108(28):11608-11613. Kingstone, A., C. K. Friesen, and M. S. Gazzaniga. 2000. Reflexive joint attention depends on lateralized cortical connections. Psychol Sci 11(2):159-166. Klevens, R. M., and R. A. Tohme. 2010. Evaluation of acute hepatitis C infection surveillance—United States, 2008. MMWR 59(43):4. Kneteman, N. M., and D. F. Mercer. 2005. Mice with chimeric human livers: Who says supermodels have to be tall? Hepatology 41(4):703-706. Köhler, G., and C. Milstein. 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256(5517):495-497. Konopka, G., J. M. Bomar, K. Winden, G. Coppola, Z. O. Jonsson, F. Gao, S. Peng, T. M. Preuss, J. A. Wohlschlegel, and D. H. Geschwind. 2009. Human- specific transcriptional regulation of CNS development genes by FOXP2. Nature 462(7270):213-217.

OCR for page 71
81 APPENDIX A Korte, T. 2010. Chimps’ future prompts debate over NM primate lab. Associated Press Online. September 22. Krilov, L. R. 2011. Respiratory syncytial virus disease: Update on treatment and prevention. Expert Rev Anti Infect Ther 9(1):27-32. Kurosaki, M., N. Enomoto, F. Marumo, and C. Sato. 1993. Rapid sequence variation of the hypervariable region of hepatitis C virus during the course of chronic infection. Hepatology 18(6):1293-1299. Kwo, P. Y., E. J. Lawitz, J. McCone, E. R. Schiff, J. M. Vierling, D. Pound, M. N. Davis, J. S. Galati, S. C. Gordon, N. Ravendhran, L. Rossaro, F. H. Anderson, I. M. Jacobson, R. Rubin, K. Koury, L. D. Pedicone, C. A. Brass, E. Chaudhri, and J. K. Albrecht. 2010. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (sprint-1): An open-label, randomised, multicentre phase 2 trial. Lancet 376(9742):705-716. Lai, C. S., S. E. Fisher, J. A. Hurst, F. Vargha-Khadem, and A. P. Monaco. 2001. A forkhead-domain gene is mutated in a severe speech and language disorder. Nature 413(6855):519-523. Lammey, M. 2011. (Alamogordo Primate Facility, Alamogordo, NM). Email to authors: IOM chimp study with file attachment: APF colony age sex breakdown.xls. May 17, 2011. Landry, J. 2011. (New Iberia Research Center, New Iberia, LA). Email to authors: IOM chimp study with file attachment: NIRC chimps count by age.xls. May 17, 2011. Lanford, R. E., B. Guerra, C. B. Bigger, H. Lee, D. Chavez, and K. M. Brasky. 2007. Lack of response to exogenous interferon-alpha in the liver of chimpanzees chronically infected with hepatitis C virus. Hepatology 46(4):999-1008. Lanford, R., B. Guerra, D. Chavez, V. L. Hodara, X. Zheng, G. Wolfgang, and D. B. Tumas. 2011. Therapeutic efficacy of a TLR7 agonist for HBV chronic infection in chimpanzees. Paper presented at 46th Annual Meeting of the European Association for the Study of the Liver, Berlin, Germany, March 30-April 3. Langford, R. E. 2011. (Texas Biomedical Research Institute, San Antonio, TX). Email to authors: Chimpanzee data from SNPRC for IOM committee with file attachment: SNPRC chimpanzee studies and biomaterials IOM 62811.pdf. June 29, 2011. Ledford, H. 2010. Chimps’ fate ignites debate. Nature 467(7315):507-508. Lindenbach, B. D., M. J. Evans, A. J. Syder, B. Wolk, T. L. Tellinghuisen, C. C. Liu, T. Maruyama, R. O. Hynes, D. R. Burton, J. A. McKeating, and C. M. Rice. 2005. Complete replication of hepatitis C virus in cell culture. Science 309(5734):623-626.

OCR for page 71
82 ASSESSING THE NECESSITY OF THE CHIMPANZEE Lohmann, V., F. Korner, J. Koch, U. Herian, L. Theilmann, and R. Bartenschlager. 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285(5424):110-113. Ma, Y., L. Poisson, G. Sanchez-Schmitz, S. Pawar, C. Qu, G. J. Randolph, W. L. Warren, E. M. Mishkin, and R. G. Higbee. 2010. Assessing the immunopotency of toll-like receptor agonists in an in vitro tissue- engineered immunological model. Immunology 130(3):374-387. MacDermot, K. D., E. Bonora, N. Sykes, A. M. Coupe, C. S. Lai, S. C. Vernes, F. Vargha-Khadem, F. McKenzie, R. L. Smith, A. P. Monaco, and S. E. Fisher. 2005. Identification of FOXP2 truncation as a novel cause of developmental speech and language deficits. Am J Hum Genet 76(6):1074-1080. Maher, L., B. White, M. Hellard, A. Madden, M. Prins, T. Kerr, and K. Page. 2010. Candidate hepatitis C vaccine trials and people who inject drugs: Challenges and opportunities. Vaccine 28(45):7273-7278. Marasco, W. A., and J. Sui. 2007. The growth and potential of human antiviral monoclonal antibody therapeutics. Nat Biotechnol 25(12):1421-1434. Marques-Bonet, T., O. A. Ryder, and E. E. Eichler. 2009. Sequencing primate genomes: What have we learned? Annu Rev Genomics Hum Genet 10:355- 386. MedImmune LLC. 2011a. A randomized, double-blind, placebo-controlled study to evaluate viral shedding of medi-559 in healthy 1 to <24 month-old children. ClinicalTrials.gov: A service of the U.S. National Institutes of Health. http://clinicaltrials.gov/ct2/show/NCT00767416?term=NCT00767416&rank= 1 NLM Idenitifier: NCT00767416 (accessed August 24, 2011). MedImmune LLC. 2011b. A study to evaluate the safety, tolerability, immunogenicity and vaccine-like viral shedding of MEDIi-534, against respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3), in healthy 6 to <24 month-old children and in 2 month-old infants. ClinicalTrials.gov: A service of the U.S. National Institutes of Health. http://clinicaltrials.gov/ct2/show/NCT00686075?term=NCT00686075&rank= 1 NLM Identifier: NCT00686075 (accessed August 24, 2011). Men, R., T. Yamashiro, A. P. Goncalvez, C. Wernly, D. J. Schofield, S. U. Emerson, R. H. Purcell, and C. J. Lai. 2004. Identification of chimpanzee fab fragments by repertoire cloning and production of a full-length humanized immunoglobulin g1 antibody that is highly efficient for neutralization of dengue type 4 virus. J Virol 78(9):4665-4674. Mercer, D. F., D. E. Schiller, J. F. Elliott, D. N. Douglas, C. Hao, A. Rinfret, W. R. Addison, K. P. Fischer, T. A. Churchill, J. R. Lakey, D. L. Tyrrell, and N. M. Kneteman. 2001. Hepatitis C virus replication in mice with chimeric human livers. Nat Med 7(8):927-933. Meuleman, P., L. Libbrecht, R. De Vos, B. de Hemptinne, K. Gevaert, J. Vandekerckhove, T. Roskams, and G. Leroux-Roels. 2005. Morphological and biochemical characterization of a human liver in a UPA-SCID mouse chimera. Hepatology 41(4):847-856.

OCR for page 71
83 APPENDIX A Meunier, J. C., J. M. Gottwein, M. Houghton, R. S. Russell, S. U. Emerson, J. Bukh, and R. H. Purcell. 2011. Vaccine-induced cross-genotype reactive neutralizing antibodies against hepatitis C virus. J Infect Dis 204(8):1186- 1190. MicroDose Therapeutx. 2011. A trial to assess the safety, tolerability, and pharmacokinetics of MDT-637 in healthy volunteers. ClinicalTrials.gov: A service of the U.S. National Institutes of Health. http://clinicaltrials.gov/ ct2/show/NCT01355016?term=nct01355016&rank=1. NLM Identifier: NCT01355016 (accessed August 24, 2011). Mikkelsen, T. S., L. W. Hillier, E. E. Eichler, M. C. Zody, D. B. Jaffe, S.-P. Yang, W. Enard, I. Hellmann, K. Lindblad-Toh, T. K. Altheide, N. Archidiacono, P. Bork, J. Butler, J. L. Chang, Z. Cheng, A. T. Chinwalla, P. deJong, K. D. Delehaunty, C. C. Fronick, L. L. Fulton, Y. Gilad, G. Glusman, S. Gnerre, T. A. Graves, T. Hayakawa, K. E. Hayden, X. Huang, H. Ji, W. J. Kent, M.-C. King, E. J. KulbokasIII, M. K. Lee, G. Liu, C. Lopez-Otin, K. D. Makova, O. Man, E. R. Mardis, E. Mauceli, T. L. Miner, W. E. Nash, J. O. Nelson, S. Pääbo, N. J. Patterson, C. S. Pohl, K. S. Pollard, K. Prüfer, X. S. Puente, D. Reich, M. Rocchi, K. Rosenbloom, M. Ruvolo, D. J. Richter, S. F. Schaffner, A. F. A. Smit, S. M. Smith, M. Suyama, J. Taylor, D. Torrents, E. Tuzun, A. Varki, G. Velasco, M. Ventura, J. W. Wallis, M. C. Wendl, R. K. Wilson, E. S. Lander, and R. H. Waterston. 2005. Initial sequence of the chimpanzee genome and comparison with the human genome. Nature 437(7055):69-87. Mohapatra, S. S., and S. Boyapalle. 2008. Epidemiologic, experimental, and clinical links between respiratory syncytial virus infection and asthma. Clin Microbiol Rev 21(3):495-504. Muller, P. Y., M. Milton, P. Lloyd, J. Sims, and F. R. Brennan. 2009. The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies. Curr Opin Biotechnol 20(6):722-729. Mundy, P., M. Gwaltney, and H. Henderson. 2010. Self-referenced processing, neurodevelopment and joint attention in autism. Autism 14(5):408-429. Murphy, B. R., S. L. Hall, J. Crowe, P. L. Collins, E. K. Subbarao, M. Connors, W. T. London, and R. M. Chanock. 1992. The use of chimpanzees in respiratory virus research. In Chimpanzee conservation and public health: Environments for the future, 1st ed., edited by J. Erwin and J. C. Landon. Rockville, MD: Diagnon Corp./Bioqual. Pp. 21-27. Nair, H., V. R. Verma, E. Theodoratou, L. Zgaga, T. Huda, E. A. Simoes, P. F. Wright, I. Rudan, and H. Campbell. 2011. An evaluation of the emerging interventions against respiratory syncytial virus (RSV)-associated acute lower respiratory infections in children. BMC Public Health 11(Suppl 3):S30. NCRR (National Center for Research Resources). 2007. Report of the chimpanzee management plan working group. http://ncrr.nih.gov/comparative_medicine/

OCR for page 71
84 ASSESSING THE NECESSITY OF THE CHIMPANZEE chimpanzee_management_program/ChimP05-22-2007.pdf (accessed July 27, 2011). NCRR. 2011a. Primate resources. http://www.ncrr.nih.gov/comparative_ medicine/resource_directory/primates.asp#alamo (accessed July 27, 2011). NCRR. 2011b. Chimpanzee management program. http://www.ncrr.nih.gov/ comparative_medicine/chimpanzee_mangementprogram/ (accessed July 27, 2011). Nelson, A. L., E. Dhimolea, and J. M. Reichert. 2010. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 9(10):767- 774. NIAID (U.S. National Institute of Allergy and Infectious Diseases). 2011. Emerging and re-emerging infectious diseases. http://www.niaid.nih.gov/ topics/emerging/Pages/list.aspx (accessed August 18, 2011). NIH. 2011. About NIH: Mission. http://nih.gov/about/mission.htm (accessed August 13, 2011). NIH (U.S. National Institutes of Health). Unpublished. Charter of the interagency animal model committee. Novavax. 2011. Safety study of respiratory syncytial virus F (RSV-F) vaccine to treat the respiratory syncytial virus in healthy adults 18 to 49 years of age (nvx 757 101). ClinicalTrials.gov: A service of the U.S. National Institute of Health. http://clinicaltrials.gov/ct2/show/NCT01290419?term=NCT01290419 NCT01290419&rank=1 NLM Identifier: NCT01290419 (accessed August 2, 2011). NRC (National Research Council). 1997. Chimpanzees in research: Strategies for their ethical care, management, and use. Washington, DC: National Academy Press. NRC. 2010. Guide for the care and use of laboratory animals, 8th ed. Washington, DC: The National Academies Press. NSF (National Science Foundation). 2011. Funding search results. http://www.nsf.gov/funding/funding_results.jsp?nsfOrgs=allorg&pubStatus =ACTIVE&queryText=chimpanzee&searchAwards=on&Submit.x=0&Sub mit.y=0 (accessed July 14, 2011). Okasha, S. 2010. Altruism researchers must cooperate. Nature 467(7316):653- 655. Olsen, D. B., M. E. Davies, L. Handt, K. Koeplinger, N. R. Zhang, S. W. Ludmerer, D. Graham, N. Liverton, M. MacCoss, D. Hazuda, and S. S. Carroll. 2011. Sustained viral response in a hepatitis C virus-infected chimpanzee via a combination of direct-acting antiviral agents. Antimicrob Agents Chemother 55(2):937-939. Pan, C. H., C. E. Greer, D. Hauer, H. S. Legg, E. Y. Lee, M. J. Bergen, B. Lau, R. J. Adams, J. M. Polo, and D. E. Griffin. 2010. A chimeric alphavirus replicon particle vaccine expressing the hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques from measles. J Virol 84(8):3798-3807.

OCR for page 71
85 APPENDIX A Parliament of the United Kingdom. 1987. Guidance on the Operation of the Animals (Scientific Procedures) Act 1986. On January 1, 1997. Act Eliz. II 1986 C.14 Section 21. United Kingdom. Pharmaceutical Business Review. 2011. Search of clinical trials for preclinical RSV programs in development for either therapeutics or prophylactics. http://clinicaltrials.pharmaceutical-business-review.com (accessed August 24, 2011). Physicians Committee for Responsible Medicine. 2011. Petition for administrative action before the National Institutes of Health, submitted to: Francis S. Collins, Director, National Institutes of Health, March 3. Ploss, A., and C. M. Rice. 2009. Towards a small animal model for hepatitis C. EMBO Rep 10(11):1220-1227. Pollack, P., and J. R. Groothuis. 2002. Development and use of palivizumab (synagis): A passive immunoprophylactic agent for RSV. J Infect Chemother 8(3):201-206. Prescott, W. A., Jr., F. Doloresco, J. Brown, and J. A. Paladino. 2010. Cost effectiveness of respiratory syncytial virus prophylaxis: A critical and systematic review. Pharmacoeconomics 28(4):279-293. Qiu, J., B. Qin, S. Rayner, C. C. Wu, R. J. Pei, S. Xu, Y. Wang, and X. W. Chen. 2011. Novel evidence suggests hepatitis B virus surface proteins participate in regulation of HBV genome replication. Virol Sin 26(2):131-138. Reichert, J. M., C. J. Rosensweig, L. B. Faden, and M. C. Dewitz. 2005. Monoclonal antibody successes in the clinic. Nat Biotechnol 23(9):1073- 1078. Reynolds, J., and CEECE (Coalition to End Experiments on Chimpanzees in Europe). 2001. Report on the Biomedical Primate Research Centre (BPRC). Brighton, UK: CEECE. Reynolds, T. 2011. Monoclonal antibody therapeutics [slide presentation]. Presented to the Committee on the Use of Chimpanzees in Biomedical and Behavioral Research, August 11, 2011, Washington, DC. Rowell, T. J. 2011. (New Iberia Research Center, New Iberia, LA). Email to authors: Chimpanzee data from NIRC for IOM committee with file attachment: studies and bio requests.pdf. June 30, 2011. Sakai, T., A. Mikami, M. Tomonaga, M. Matsui, J. Suzuki, Y. Hamada, M. Tanaka, T. Miyabe-Nishiwaki, H. Makishima, M. Nakatsukasa, and T. Matsuzawa. 2011. Differential prefrontal white matter development in chimpanzees and humans. Curr Biol 21(16):1397-1402. SCHER (Scientific Committee on Health and Environmental Risks). 2009. The need for non-human primates in biomedical research, production and testing of products and devices. Adopted at the 27th plenary on 13 January 2009. European Commission, Health and Protection Consumer Directorate- General. Brussels. Schofield, D. J., J. Glamann, S. U. Emerson, and R. H. Purcell. 2000. Identification by phage display and characterization of two neutralizing

OCR for page 71
86 ASSESSING THE NECESSITY OF THE CHIMPANZEE chimpanzee monoclonal antibodies to the hepatitis E virus capsid protein. J Virol 74(12):5548-5555. Schofield, D. J., W. Satterfield, S. U. Emerson, and R. H. Purcell. 2002. Four chimpanzee monoclonal antibodies isolated by phage display neutralize hepatitis A virus. Virology 292(1):127-136. Schofield, D. J., R. H. Purcell, H. T. Nguyen, and S. U. Emerson. 2003. Monoclonal antibodies that neutralize HEVrecognize an antigenic site at the carboxyterminus of an ORF2 protein vaccine. Vaccine 22(2):257-267. Secretary of State for the Home Department and Parliament of the United Kingdom. 1998. Report of the Animal Procedures Committee for 1997. London, UK: Secretary of State for the Home Department and Parliament. Shadman, K. A., and E. R. Wald. 2011. A review of palivizumab and emerging therapies for respiratory syncytial virus. Expert Opin Biol Ther, http://www.ncbi.nlm.nih.gov/pubmed/21831008 (accessed August 11, 2011). Shah, J. N., and R. F. Chemaly. 2011. Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Blood 117(10):2755- 2763. Sheehy, P., B. Mullan, I. Moreau, E. Kenny-Walsh, F. Shanahan, M. Scallan, and L. J. Fanning. 2007. In vitro replication models for the hepatitis C virus. J Viral Hepat 14(1):2-10. Shoukry, N. H., A. Grakoui, M. Houghton, D. Y. Chien, J. Ghrayeb, K. A. Reimann, and C. M. Walker. 2003. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 197(12):1645-1655. Strickland, G. T., S. S. El-Kamary, P. Klenerman, and A. Nicosia. 2008. Hepatitis C vaccine: Supply and demand. Lancet Infect Dis 8(6):379-386. Su, A. I., J. P. Pezacki, L. Wodicka, A. D. Brideau, L. Supekova, R. Thimme, S. Wieland, J. Bukh, R. H. Purcell, P. G. Schultz, and F. V. Chisari. 2002. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci USA 99(24):15669-15674. Suomi, S. J. 2006. Risk, resilience, and gene X environment interactions in rhesus monkeys. Ann N Y Acad Sci 1094:52-62. Tabrizi, M. A., G. G. Bornstein, S. L. Klakamp, A. Drake, R. Knight, and L. Roskos. 2009. Translational strategies for development of monoclonal antibodies from discovery to the clinic. Drug Discov Today 14(5-6):298- 305. Taglialatela, J. P., J. L. Russell, J. A. Schaeffer, and W. D. Hopkins. 2008. Communicative signaling activates “Broca’s” homolog in chimpanzees. Curr Biol 18(5):343-348. Tayyari, F., D. Marchant, T. J. Moraes, W. Duan, P. Mastrangelo, and R. G. Hegele. 2011. Identification of nucleolin as a cellular receptor for human respiratory syncytial virus. Nat Med 17(9):1132-1135. Thimme, R., J. Bukh, H. C. Spangenberg, S. Wieland, J. Pemberton, C. Steiger, S. Govindarajan, R. H. Purcell, and F. V. Chisari. 2002. Viral and

OCR for page 71
87 APPENDIX A immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci USA 99(24):15661-15668. Thomson, M., M. Nascimbeni, M. B. Havert, M. Major, S. Gonzales, H. Alter, S. M. Feinstone, K. K. Murthy, B. Rehermann, and T. J. Liang. 2003. The clearance of hepatitis C virus infection in chimpanzees may not necessarily correlate with the appearance of acquired immunity. J Virol 77(2):862-870. U.S. Office of Laboratory Animal Welfare. 2002. Public Health Service policy on humane care and use of laboratory animals. http://grants.nih.gov/grants/ http://grants.nih.gov/grants/olaw/references/phspol.htm (accessed August 18, 2011). Valenzuela, D. M., A. J. Murphy, D. Frendewey, N. W. Gale, A. N. Economides, W. Auerbach, W. T. Poueymirou, N. C. Adams, J. Rojas, J. Yasenchak, R. Chernomorsky, M. Boucher, A. L. Elsasser, L. Esau, J. Zheng, J. A. Griffiths, X. Wang, H. Su, Y. Xue, M. G. Dominguez, I. Noguera, R. Torres, L. E. Macdonald, A. F. Stewart, T. M. DeChiara, and G. D. Yancopoulos. 2003. High-throughput engineering of the mouse genome coupled with high-resolution expression analysis. Nat Biotechnol 21(6):652-659. Valerio, L. G., Jr. 2011. In silico toxicology models and databases as FDA Critical Path Initiative toolkits. Hum Genomics 5(3):200-207. Verstrepen, B. E., E. Depla, C. S. Rollier, G. Mares, J. A. Drexhage, S. Priem, E. J. Verschoor, G. Koopman, C. Granier, M. Dreux, F. L. Cosset, G. Maertens, and J. L. Heeney. 2011. Clearance of genotype 1B hepatitis C virus in chimpanzees in the presence of vaccine-induced E1-neutralizing antibodies. J Infect Dis 204(6):837-844. Vertex Pharmaceuticals Incorporated. 2011. Telaprevir 375-mg film-coated tablet for the treatment of genotype 1 chronic hepatitis C. hhtp://www.fda.gov/down loads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AntiviralDrugs AdvisoryCommittee/UCM252562.pdf (accessed September 13, 2011). Vogel, G. 2001. Dutch end chimp studies. ScienceNOW. http://news.sciencemag. http://news.sciencemag.org/sciencenow/2001/05/01-01.html (accessed Sep- tember 30, 2011). Wang, C. C., E. Krantz, J. Klarquist, M. Krows, L. McBride, E. P. Scott, T. Shaw-Stiffel, S. J. Weston, H. Thiede, A. Wald, and H. R. Rosen. 2007. Acute hepatitis C in a contemporary U.S. cohort: Modes of acquisition and factors influencing viral clearance. J Infect Dis 196(10):1474-1482. Waterston, R. H., K. Lindblad-Toh, E. Birney, J. Rogers, J. F. Abril, P. Agarwal, R. Agarwala, R. Ainscough, M. Alexandersson, P. An, S. E. Antonarakis, J. Attwood, R. Baertsch, J. Bailey, K. Barlow, S. Beck, E. Berry, B. Birren, T. Bloom, P. Bork, M. Botcherby, N. Bray, M. R. Brent, D. G. Brown, S. D. Brown, C. Bult, J. Burton, J. Butler, R. D. Campbell, P. Carninci, S. Cawley, F. Chiaromonte, A. T. Chinwalla, D. M. Church, M. Clamp, C. Clee, F. S. Collins, L. L. Cook, R. R. Copley, A. Coulson, O. Couronne, J. Cuff, V. Curwen, T. Cutts, M. Daly, R. David, J. Davies, K. D. Delehaunty, J. Deri, E. T. Dermitzakis, C. Dewey, N. J. Dickens, M. Diekhans, S. Dodge,

OCR for page 71
88 ASSESSING THE NECESSITY OF THE CHIMPANZEE I. Dubchak, D. M. Dunn, S. R. Eddy, L. Elnitski, R. D. Emes, P. Eswara, E. Eyras, A. Felsenfeld, G. A. Fewell, P. Flicek, K. Foley, W. N. Frankel, L. A. Fulton, R. S. Fulton, T. S. Furey, D. Gage, R. A. Gibbs, G. Glusman, S. Gnerre, N. Goldman, L. Goodstadt, D. Grafham, T. A. Graves, E. D. Green, S. Gregory, R. Guigo, M. Guyer, R. C. Hardison, D. Haussler, Y. Hayashizaki, L. W. Hillier, A. Hinrichs, W. Hlavina, T. Holzer, F. Hsu, A. Hua, T. Hubbard, A. Hunt, I. Jackson, D. B. Jaffe, L. S. Johnson, M. Jones, T. A. Jones, A. Joy, M. Kamal, E. K. Karlsson, D. Karolchik, A. Kasprzyk, J. Kawai, E. Keibler, C. Kells, W. J. Kent, A. Kirby, D. L. Kolbe, I. Korf, R. S. Kucherlapati, E. J. Kulbokas, D. Kulp, T. Landers, J. P. Leger, S. Leonard, I. Letunic, R. Levine, J. Li, M. Li, C. Lloyd, S. Lucas, B. Ma, D. R. Maglott, E. R. Mardis, L. Matthews, E. Mauceli, J. H. Mayer, M. McCarthy, W. R. McCombie, S. McLaren, K. McLay, J. D. McPherson, J. Meldrim, B. Meredith, J. P. Mesirov, W. Miller, T. L. Miner, E. Mongin, K. T. Montgomery, M. Morgan, R. Mott, J. C. Mullikin, D. M. Muzny, W. E. Nash, J. O. Nelson, M. N. Nhan, R. Nicol, Z. Ning, C. Nusbaum, M. J. O’Connor, Y. Okazaki, K. Oliver, E. Overton-Larty, L. Pachter, G. Parra, K. H. Pepin, J. Peterson, P. Pevzner, R. Plumb, C. S. Pohl, A. Poliakov, T. C. Ponce, C. P. Ponting, S. Potter, M. Quail, A. Reymond, B. A. Roe, K. M. Roskin, E. M. Rubin, A. G. Rust, R. Santos, V. Sapojnikov, B. Schultz, J. Schultz, M. S. Schwartz, S. Schwartz, C. Scott, S. Seaman, S. Searle, T. Sharpe, A. Sheridan, R. Shownkeen, S. Sims, J. B. Singer, G. Slater, A. Smit, D. R. Smith, B. Spencer, A. Stabenau, N. Stange-Thomann, C. Sugnet, M. Suyama, G. Tesler, J. Thompson, D. Torrents, E. Trevaskis, J. Tromp, C. Ucla, A. Ureta-Vidal, J. P. Vinson, A. C. Von Niederhausern, C. M. Wade, M. Wall, R. J. Weber, R. B. Weiss, M. C. Wendl, A. P. West, K. Wetterstrand, R. Wheeler, S. Whelan, J. Wierzbowski, D. Willey, S. Williams, R. K. Wilson, E. Winter, K. C. Worley, D. Wyman, S. Yang, S. P. Yang, E. M. Zdobnov, M. C. Zody, and E. S. Lander. 2002. Initial sequencing and comparative analysis of the mouse genome. Nature 420(6915):520-562. Watson, H. 2011. Chimpanzees in biomedical research [slide presentation]. Presented to the Committee on the Use of Chimpanzees in Biomedical and Behavioral Research, May 26, 2011, Washington, DC. Weisman, L. E. 2009. Respiratory syncytial virus (RSV) prevention and treatment: Past, present, and future. Cardiovasc Hematol Agents Med Chem 7(3):223-233. WHO (World Health Organization). 2003. Netherlands. Law of 2 October 2003 (stb. 399) amending the law on animal experimentation. International Digest of Health Legislation. http://apps.who.int/idhl-rils/results.cfm? language=english&type=ByIssue&intDigestVolume=54&intIssue=4&strTopic Code=XIA (accessed August 24, 2011). WHO. 2011. Hepatitis C. World Health Organization (WHO) Media Centre. Geneva.

OCR for page 71
89 APPENDIX A Williams, I. T., B. P. Bell, W. Kuhnert, and M. J. Alter. 2011. Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006. Arch Intern Med 171(3):242-248. Wright, M., and G. Piedimonte. 2011. Respiratory syncytial virus prevention and therapy: Past, present, and future. Pediatr Pulmonol 46(4):324-347. Wu, G. Y., M. Konishi, C. M. Walton, D. Olive, K. Hayashi, and C. H. Wu. 2005. A novel immunocompetent rat model of HCV infection and hepatitis. Gastroenterology 128(5):1416-1423. Yerkes National Primate Research Center. 2011. About. http://www.yerkes.emory. edu/about/index.html (accessed July 27, 2011). Zanetti, A. R., E. Tanzi, S. Paccagnini, N. Principi, G. Pizzocolo, M. L. Caccamo, E. D’Amico, G. Cambie, and L. Vecchi. 1995. Mother-to-infant transmission of hepatitis C virus. Lombardy study group on vertical HCV transmission. Lancet 345(8945):289-291. Zhong, J., P. Gastaminza, G. Cheng, S. Kapadia, T. Kato, D. R. Burton, S. F. Wieland, S. L. Uprichard, T. Wakita, and F. V. Chisari. 2005. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA 102(26):9294- 9299.

OCR for page 71